Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
South Korea · Delayed Price · Currency is KRW 11,400
+220 (1.97%)
At close: Apr 2, 2026
KRX:007570 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 272,422 | 268,678 | 266,669 | 247,773 | 242,511 |
Other Revenue | - | - | -0 | -0 | -0 |
| 272,422 | 268,678 | 266,669 | 247,773 | 242,511 | |
Revenue Growth (YoY) | 1.39% | 0.75% | 7.63% | 2.17% | -29.37% |
Cost of Revenue | 156,142 | 157,461 | 150,265 | 139,579 | 137,865 |
Gross Profit | 116,280 | 111,217 | 116,404 | 108,194 | 104,646 |
Selling, General & Admin | 82,088 | 73,907 | 73,605 | 69,591 | 69,145 |
Research & Development | 26,099 | 24,740 | 23,748 | 22,395 | 16,829 |
Other Operating Expenses | 2,024 | 1,967 | 1,954 | 1,832 | 1,764 |
Operating Expenses | 111,318 | 101,595 | 100,024 | 93,945 | 89,458 |
Operating Income | 4,963 | 9,622 | 16,379 | 14,249 | 15,188 |
Interest Expense | -3,031 | -2,932 | -3,225 | -2,132 | -1,894 |
Interest & Investment Income | 502.77 | 619.4 | 361.43 | 279.06 | 348.43 |
Earnings From Equity Investments | -843.99 | 2,083 | -13,425 | 10,754 | 9,236 |
Currency Exchange Gain (Loss) | -188.29 | 1,222 | -1,011 | -551.53 | 1,265 |
Other Non Operating Income (Expenses) | 11,730 | 263.21 | -928.6 | 1,288 | -2,347 |
EBT Excluding Unusual Items | 13,132 | 10,878 | -1,849 | 23,887 | 21,797 |
Gain (Loss) on Sale of Investments | - | 27.78 | 8.92 | -24.78 | - |
Gain (Loss) on Sale of Assets | 90.04 | -8.96 | 0.53 | 21.22 | 2.86 |
Asset Writedown | 37 | 2.15 | 40.51 | -36.82 | 263.19 |
Pretax Income | 13,260 | 10,899 | -1,799 | 23,846 | 22,063 |
Income Tax Expense | 6,127 | 1,617 | 230.97 | 4,040 | 7,311 |
Earnings From Continuing Operations | 7,133 | 9,282 | -2,030 | 19,806 | 14,752 |
Minority Interest in Earnings | -227.99 | -250.39 | -378.26 | -420.96 | -719.83 |
Net Income | 6,905 | 9,032 | -2,409 | 19,385 | 14,032 |
Preferred Dividends & Other Adjustments | - | - | -88.03 | 452.64 | - |
Net Income to Common | 6,905 | 9,032 | -2,321 | 18,933 | 14,032 |
Net Income Growth | -23.55% | - | - | 38.15% | 28.98% |
Shares Outstanding (Basic) | 18 | 18 | 18 | 18 | 18 |
Shares Outstanding (Diluted) | 18 | 18 | 18 | 18 | 18 |
Shares Change (YoY) | -0.11% | 2.29% | -0.59% | -0.44% | - |
EPS (Basic) | 375.00 | 490.00 | -128.79 | 1044.53 | 770.78 |
EPS (Diluted) | 375.00 | 490.00 | -131.00 | 1044.53 | 770.78 |
EPS Growth | -23.47% | - | - | 35.52% | 29.11% |
Free Cash Flow | 6,323 | -32,585 | 8,736 | 1,938 | 39,057 |
Free Cash Flow Per Share | 343.42 | -1767.81 | 484.85 | 106.90 | 2145.40 |
Dividend Per Share | - | - | 150.000 | - | - |
Gross Margin | 42.68% | 41.39% | 43.65% | 43.67% | 43.15% |
Operating Margin | 1.82% | 3.58% | 6.14% | 5.75% | 6.26% |
Profit Margin | 2.54% | 3.36% | -0.87% | 7.64% | 5.79% |
Free Cash Flow Margin | 2.32% | -12.13% | 3.28% | 0.78% | 16.11% |
EBITDA | 13,307 | 19,446 | 28,350 | 26,016 | 26,415 |
EBITDA Margin | 4.88% | 7.24% | 10.63% | 10.50% | 10.89% |
D&A For EBITDA | 8,344 | 9,824 | 11,971 | 11,767 | 11,227 |
EBIT | 4,963 | 9,622 | 16,379 | 14,249 | 15,188 |
EBIT Margin | 1.82% | 3.58% | 6.14% | 5.75% | 6.26% |
Effective Tax Rate | 46.21% | 14.84% | - | 16.94% | 33.14% |
Advertising Expenses | 6,715 | 6,409 | 6,264 | 6,312 | 7,205 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.